Verrica Pharmaceuticals

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Verrica Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 2 currently recruiting 6 completed top decile by trial count

Verrica Pharmaceuticals: 9 sponsored US clinical trials, 2 recruiting.

Verrica Pharmaceuticals sponsors 9 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 6 completed. 5 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Common Warts (Verruca Vulgaris), with 1 trials.

Top-decile sponsor footprint

Verrica Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 3

Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)

NCT07457918
RECRUITING Phase 3

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)

NCT07246590
NOT YET RECRUITING Phase 3

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)

NCT07637734
COMPLETED Phase 2

Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma

NCT05188729
COMPLETED Phase 2

A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts

NCT03981822
COMPLETED Phase 2

Cantharidin and Occlusion in Verruca Epithelium

NCT03487549
COMPLETED Phase 3

Cantharidin Application in Molluscum Patients-1

NCT03377790
COMPLETED Phase 3

Cantharidin Application in Molluscum Patients

NCT03377803
COMPLETED Phase 2

Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.

NCT03186378

Phase Distribution

PhaseTrial count
Phase 2 4
Phase 3 5

Therapeutic Areas

Common Warts (Verruca Vulgaris) 1
Common Warts 1
Human Papilloma Virus (HPV) 1
Warts 1

What is open in the Verrica Pharmaceuticals pipeline

2 recruiting of 9 indexed (22% open); 6 completed (67%).

Phase mix: 5 late (III/IV) vs 4 early (I/II) (balanced across stages).

Top condition: Common Warts (Verruca Vulgaris) (1 trial), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Verrica Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 9 registered trials and 22% open enrollment, not the therapeutic-area sidebar.

Verrica Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 8101214161820 0%10%20%30%40%50% Total trials Recruiting share Verrica Pharmaceuticals4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyALX OncologyBiosense WebsterEnglewood Hospital and Medical CenterEnsysce Biosciences
Verrica Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Verrica Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 22% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Verrica Pharmaceuticals page

9 registered trials is a research-attention snapshot, not an endorsement of Verrica Pharmaceuticals or any single study.

  • 2 of Verrica Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Common Warts (Verruca Vulgaris) is the condition Verrica Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Common Warts (Verruca Vulgaris) trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Verrica Pharmaceuticals pipeline card: 9 registered trials from official public datasets.Report a data error.